• Users Online: 158
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2016  |  Volume : 41  |  Issue : 4  |  Page : 206-210

Dipeptidyl peptidase-4 (CD26): a prognostic marker in patients with B-cell chronic lymphocytic leukemia

1 Department of Clinical Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt
2 Department of Internal Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt

Correspondence Address:
Hossam Hodeib
Department of Clinical Pathology, Faculty of Medicine, Tanta University, El Geish Street, Tanta, 31511
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1110-1067.198650

Rights and Permissions

Introduction B-cell chronic lymphocytic leukemia (B-CLL) is an incurable disease; nevertheless, its prognosis varies widely among patients. CD26 is considered a cell adhesion molecule. It is suggested that CD26 expression is involved in tumor growth, invasion, and metastasis. Aim The aim of this study was to assess the prognostic value of dipeptidyl peptidase-4 (CD26) in patients with B-CLL and its relation to the clinical and laboratory parameters. Patients and methods This case–control study was carried out from April 2013 to April 2016, and it was performed on 75 newly diagnosed B-CLL patients admitted at Hematology and Oncology Unit, Department of Internal Medicine, Tanta University Hospital, Egypt; 30 apparently healthy individuals were involved in the study as the control group. Dipeptidyl peptidase-4 (CD26) expression was evaluated by flow cytometry. Results The main finding in this study was that CD26 expression was increased in B-CLL patients in comparison with normal subjects. There was also a positive correlation between white blood cell count, absolute lymphocytosis, clinical staging of B-CLL patients, and CD26 expression. Overall survival (OS) and disease-free survival (DFS) were shorter in B-CLL patients with positive CD26 expression compared with patients with negative CD26 expression. Patients with positive CD26 expression had significantly shorter OS (16 vs. 20 months) and significantly lower DFS (6 vs. 16.5 months) at 24 months compared with those with negative CD26 expression. Conclusion CD26 expression was significantly higher in B-CLL patients compared with healthy subjects, and its expression among B-CLL patients correlated with poor laboratory data, clinical staging, OS, and DFS, and thus it may play a role in prognosis of B-CLL. CD26 could be used as a prognostic marker either alone or in combination with other markers in assessment of B-CLL patients.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded195    
    Comments [Add]    
    Cited by others 1    

Recommend this journal